COMPOUNDING CAPABILITIES

Icon Group’s compounding arm, Slade Health assists hospitals with clinical trials by providing compounding services from our TGA / Medsafe-licensed facilities. Currently supporting over 200 clinical trials, our experience covers Phase I-IV studies, primarily in oncology and haematology.

Quality clinical trials

Slade Health’s clinical trials service includes national clinical trial co-ordination among its TGA / Medsafe-licensed compounding facilities to ensure relevant criteria is met for the compounding of investigational products. Each compounding facility has dedicated clinical trials team members who have complete oversight over the management and segregated storage of clinical trial drugs in validated and monitored equipment.

Slade Health also supports the administrative work required in clinical trials by providing relevant manufacturing records and maintaining training documentation to always guarantee compliance to Good Clinical Practice (GCP) and Good Manufacturing Process (GMP).

With validated shippers, Slade can assure the safe and secure cold chain or ambient transport of clinical trial products to hospitals on time.

Serviced 246 clinical trials in Australia, 70% of which are in Phase II / III

Stability laboratory

Since its opening in March 2022, the Drug Stability Testing and Research Laboratory has worked on the generation of scientific data to ensure the quality and stability of the products manufactured in Slade Health. The data generated in the lab has been used to support the extension of the shelf-life of products from 24 hours to 90 days. The extension of the shelf life provides great flexibility to patient treatment, enabling Slade to deliver these products to rural and remote locations across Australia, and allow patients to receive their treatment closer to home.

The Drug Stability Testing and Research Laboratory has a state-of-the-art facility that is used to develop and validate analytical and biological methods that are specific to each product. The laboratory also supports the testing of devices and containers used in the manufacturing process ensuring that each component of the final product is of the highest quality. In 2022 and beyond, the laboratory team will expand to facilitate more product testing and ultimately improve access to care.

90% oncology, 10% non-oncology

Compounded over 3697 clinical trial products

Established clinical trial presence in New Zealand with successful onboarding of 38 clinical trials from hospital partner, Te Toka Tumai

Stability laboratory

Increasing shelflife to 90 days for certain molecules